EBV阳性炎性滤泡树突细胞肉瘤的临床病理与分子遗传特征
该研究回顾12例EBV阳性炎性滤泡树突细胞肉瘤(EBV+IFDCS)与6例传统FDCS,分析临床、形态、免疫组化、原位杂交及靶向测序数据。EBV+IFDCS好发于女性,形态分经典、血管瘤样/硬化及淋巴瘤样亚型,IgG4、EBER、SMA表达更高,SSTR2、EGFR、STAT3更低。EBV+IFDCS无进展生存显著优于FDCS(3年PFS 66.67% vs 16.67%,P<0.05)。
要点
- EBV+IFDCS多见于女性,形态分经典、血管瘤样/硬化及淋巴瘤样亚型。
- EBV+IFDCS中IgG4、EBER、SMA表达显著高于FDCS,SSTR2、EGFR、STAT3显著更低。
- EBV+IFDCS无进展生存显著优于FDCS,3年PFS分别为66.67%和16.67%。
核心结论
- EBV+IFDCS具有独特的临床、形态、免疫、预后及分子细胞遗传学特征。
研究设计与样本
- 回顾性分析12例EBV+IFDCS与6例传统FDCS的临床、形态、免疫组化、原位杂交及高通量DNA靶向测序数据并随访。
主要发现
- EBV+IFDCS患者年龄21至84岁,平均52.3岁,男女比1:5;末次随访全部存活,2例复发转移。
- 形态分经典4例、血管瘤样/硬化4例、淋巴瘤样4例,其中2例伴上皮样肉芽肿。
- 所有EBV+IFDCS显示FDC标志物(CD21、CD23、CD35、CXCL13)异质性表达及SMA表达。
- EBV+IFDCS中IgG4、EBER、SMA表达显著高于FDCS(P<0.05),SSTR2、EGFR、STAT3显著更低(P<0.05)。
- 经典亚型EBER平均值显著更高(P=0.022)。
关键数值与推荐
- 4例分子分析中,1例携带CDKN1C、PDGFRA、MSH2、FANCG、MLH1、ALK、RUNX1胚系突变。
- 3例存在MTHFR基因SNP变异,2例存在NQO1基因SNP变异。
- 突变基因KEGG通路分析显著富集于cAMP信号通路。
- EBV+IFDCS中位PFS未达到(NR),FDCS为5个月(HR=7.76)。
- 3年PFS率分别为66.67%和16.67%,EBV+IFDCS中位PFS显著更长(P<0.05)。
临床怎么用
- 诊断EBV+IFDCS需结合形态分型、FDC标志物异质性表达及EBER原位杂交。
- IgG4、SMA高表达及SSTR2、EGFR、STAT3低表达有助于与FDCS鉴别。
- EBV+IFDCS预后较好,但仍需随访监测复发转移。
局限性
- 样本量小(EBV+IFDCS 12例,FDCS 6例),分子分析仅4例。
- 单中心回顾性研究,随访时间及治疗信息未详细报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell (FDC) sarcoma (EBV + IFDCS) is a rare entity, and its histopathological characteristics have not been fully described. This study aimed to investigate the clinical characteristics, pathological features, and molecular genetic profiles of EBV + IFDCS to improve our understanding of these lesions. A total of 12 EBV + IFDCS specimens were obtained from patients in our pathology diagnostic center. The clinical data, morphology, immunohistochemistry, in situ hybridization, and high-throughput DNA-targeted sequencing data were collected, and follow-up data were analyzed. These data were compared with those of 6 patients with traditional FDCS. The patients with EBV + IFDCS ranged from 21 to 84 years old, with a mean age of 52.3 years and a male-to-female ratio of 1:5. At the last follow-up, all patients were alive, with 2 experiencing recurrence and metastasis. In these cases, four were classified as the classical subtype, four as the angiomatoid/sclerosing subtype, and four as the lymphoma-like subtype, with two cases also exhibiting epithelioid granulomas. All patients exhibited heterogeneous expression of follicular dendritic cell markers (CD21, CD23, CD35, and CXCL13) alongside the fibroblast marker SMA, with significantly higher expressions of IgG4, EBER, and SMA in EBV + IFDCS patients compared to FDCS patients (P < 0.05). Conversely, SSTR2, EGFR, and STAT3 expression were significantly lower in the EBV + IFDCS group (P < 0.05). The average value of EBER was significantly higher in the classical subtype group (P = 0.022). Among the four cases of EBV + IFDCS analyzed for molecular genetic features, one patient exhibited germline mutations in the CDKN1C, PDGFRA, MSH2, FANCG, MLH1, ALK, and RUNX1 genes; three exhibited simultaneous SNP variations in the MTHFR gene; and two exhibited simultaneous SNP variations in the NQO1 gene. We conducted KEGG pathway analysis on the mutant genes, revealing significant enrichment in the cAMP signaling pathway, which plays a crucial role in tumor development. Survival analysis demonstrated that the median PFS rates were not reached (NR) for EBV + IFDCS patients, compared to 5 months (HR = 7.76) for FDCS patients. The 3-year PFS rates were 66.67% and 16.67%, respectively. Compared with the FDCS group, EBV + IFDCS patients had a significantly longer median PFS time (p < 0.05). In conclusion, EBV + IFDCS represents a group of tumors with unique clinical, morphological, immunological, prognostic, and molecular cytogenetic characteristics.
引用
- Chen S, You Z, Chen X, et al. Clinicopathological and molecular genetic insights into EBV-positive inflammatory follicular dendritic cell sarcoma. Hum Pathol. 2024. PMID: 39370049. doi:10.1016/j.humpath.2024.105668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。